PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, ...

LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...

The "Clinical Snapshot" series provides a concise examination of a clinical presentation including history, treatment, patient education, and nursing measures. Using the format here, you are invited ...

Please provide your email address to receive an email when new articles are posted on . At week 28, 88% of patients treated with combination therapy achieved 75% disease severity reduction vs. 47% on ...

Dear Anon.: Nobody knows what causes lichen planus, an uncommon (less than 1% of people) skin condition that may also affect the mouth or vagina. It most often occurs during the ages of 30 to 60. It ...

Please provide your email address to receive an email when new articles are posted on . All patients treated with baracitinib for lichen planus had a response at week 12. After 1 week of treatment, 37 ...

Sometimes it takes trying to explain something to someone else in order to understand how much you don’t understand. Let me explain. Once I was gathering material for a doctor talk on lichen (LIKE-en) ...

A survey of US dermatologists revealed low screening rates for common comorbidities in patients with lichen planus (LP), with significant reliance on topical treatments. An anonymous survey with ...